Bladder cancer Overview

Bladder cancer (BC) is the most common neoplasm of the urinary system. The wall of the bladder has several layers. Each layer is made up of different kinds of cells and BC begins when healthy cells in the bladder lining—most commonly urothelial cells—change and grow out of control, forming a mass called a tumor.

“Bladder cancer Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Bladder cancer Market.

The Bladder cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Bladder cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Bladder cancer treatment therapies with a considerable amount of success over the years. Bladder cancer Key players such as – Ractigen Therapeutics, XNK Therapeutics, Vaxiion Therapeutics, Vyriad, Inc., Istari Oncology Inc., Theralase Technologies Inc., Taiho Oncology, Inc., Lepu Biopharma CO.,Ltd., Janssen Research & Development, LLC, Asieris Pharmaceuticals, and others, are developing therapies for the Bladder cancer treatment 

• Bladder cancer Emerging therapies such as – RAG-01, XNK03, VAX014, MV-NIS, Lerapolturev, TLD-1433, Futibatinib, HX-008, TAR-200, APL-1202, and others are expected to have a significant impact on the Bladder cancer market in the coming years.   
• In September 2021, Asieris Pharmaceuticals initiated a multi-center, randomized, open-label, parallel controlled phase III clinical trial to evaluate the clinical safety and efficacy of APL-1202 as a single-agent oral treatmen tversus intravesical instillation of epirubicin hydrochloride in naïve intermediate-risk non-muscle invasive bladder cancer(NMIBC) Patients

Route of Administration

Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Bladder cancer Pipeline Therapeutics Assessment

• Bladder cancer Assessment by Product Type
• Bladder cancer By Stage and Product Type
• Bladder cancer Assessment by Route of Administration
• Bladder cancer By Stage and Route of Administration
• Bladder cancer Assessment by Molecule Type
• Bladder cancer by Stage and Molecule Type

DelveInsight’s Bladder cancer Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Bladder cancer Therapeutics Market include:

Key companies developing therapies for Bladder cancer are – CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm Co., Ltd., ImmunityBio, Inc., Hamlet Pharma AB, Asieris Pharmaceuticals, Pfizer, Taizhou Hanzhong biomedical co. LTD, Protara Therapeutics, CicloMed LLC, enGene, Inc., Emtora Biosciences, Theralase Inc.,  Vaxiion Therapeutics, Janssen Research & Development, LLC, Astellas Pharma, RemeGen Co., Ltd., UroGen Pharma Ltd., Flame Biosciences, Aura Biosciences, BeiGene, Incyte Corporation, QED Therapeutics, G1 Therapeutics, AN0025, Kyowa Kirin, Inc., Infinity Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., HiberCell, Inc., Ikena Oncology, Genentech, Fusion Pharmaceuticals, GI Innovation,SOTIO Biotech AG, Celon Pharma SA, 4D Pharma PLC, Keythera Pharmaceuticals, Quadriga Biosciences, Inc., NeoTX Therapeutics Ltd., Mirati Therapeutics, NGM Biopharmaceuticals, TransThera Biosciences, Ocellaris Pharma, Palleon Pharmaceuticals, Medicenna Therapeutics, Klus Pharma, Novartis, Toray Industries, Carisma Therapeutics, Avacta Life Sciences Ltd, Seagen Inc., Elevation Oncology, Corvus Pharmaceuticals, ADC Therapeutics S.A., IO Biotech, Byondis B.V., Takara Bio, Seven and Eight Biopharmaceuticals, Dragonfly Therapeutics, InnoCare Pharma, and others.

Emerging Bladder cancer Drugs Under Different Phases of Clinical Development Include:

• RAG-01: Ractigen Therapeutics
• XNK03: XNK Therapeutics
• VAX014: Vaxiion Therapeutics
• MV-NIS: Vyriad, Inc.
• Lerapolturev: Istari Oncology Inc.
• TLD-1433: Theralase Technologies Inc.
• Futibatinib: Taiho Oncology, Inc.
• HX-008: Lepu Biopharma CO.,Ltd.
• TAR-200: Janssen Research & Development, LLC
• APL-1202: Asieris Pharmaceuticals

Get a Free Sample PDF Report to know more about Bladder cancer Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/bladder-cancer-pipeline-insight

Bladder cancer Pipeline Analysis:

The Bladder cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Bladder cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Bladder cancer Treatment.
• Bladder cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Bladder cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Bladder cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Bladder cancer product details are provided in the report. Download the Bladder cancer pipeline report to learn more about the emerging Bladder cancer therapies

Bladder cancer Pipeline Market Drivers

• Increase in the number of patients suffering from non-muscle invasive bladder cancer
• Development of novel therapies and favorable government policies

Bladder cancer Pipeline Market Barriers

• Identifying the patient population with specific mutations for targeted therapy regimens
• Lack of awareness about the advanced cancer therapies

Scope of Bladder cancer Pipeline Drug Insight    

• Coverage: Global
• Key Bladder cancer Companies: Ractigen Therapeutics, XNK Therapeutics, Vaxiion Therapeutics, Vyriad, Inc., Istari Oncology Inc., Theralase Technologies Inc., Taiho Oncology, Inc., Lepu Biopharma CO.,Ltd., Janssen Research & Development, LLC, Asieris Pharmaceuticals, and others
• Key Bladder cancer Therapies: RAG-01, XNK03, VAX014, MV-NIS, Lerapolturev, TLD-1433, Futibatinib, HX-008, TAR-200, APL-1202, and others
• Bladder cancer Therapeutic Assessment: Bladder cancer current marketed and Bladder cancer emerging therapies
• Bladder cancer Market Dynamics: Bladder cancer market drivers and Bladder cancer market barriers 

Request for Sample PDF Report for Bladder cancer Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Bladder cancer drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services